Her main research concerns Myeloid leukemia, Leukemia, Internal medicine, Cancer research and Immunology. Her Myeloid leukemia research includes themes of Cancer, Enasidenib, Gene expression profiling, Myelodysplastic syndromes and NPM1. Her Leukemia study integrates concerns from other disciplines, such as Myeloid, BAALC, Cytogenetics and Fms-Like Tyrosine Kinase 3.
Her work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Surgery and Oncology. Her Cancer research research incorporates elements of Mutation, Germline mutation, Somatic evolution in cancer, Regulation of gene expression and Genetic heterogeneity. Her research integrates issues of Acute promyelocytic leukemia, Retinoic acid, Stem cell and Janus kinase 2 in her study of Immunology.
Konstanze Döhner mainly investigates Myeloid leukemia, Internal medicine, Cancer research, Leukemia and Oncology. The various areas that Konstanze Döhner examines in her Myeloid leukemia study include Myeloid, Molecular biology, NPM1 and Gene expression profiling. Her work in Internal medicine covers topics such as Gene mutation which are related to areas like Neuroblastoma RAS viral oncogene homolog.
In her research on the topic of Cancer research, Progenitor cell is strongly related with Haematopoiesis. Konstanze Döhner interconnects Acute promyelocytic leukemia, Adult Acute Myeloid Leukemia, Bone marrow and Survival rate in the investigation of issues within Leukemia. Her biological study spans a wide range of topics, including Bioinformatics, Midostaurin, Hematology, Cumulative incidence and Hazard ratio.
Her scientific interests lie mostly in Internal medicine, Myeloid leukemia, Oncology, Cancer research and Leukemia. Internal medicine is frequently linked to Gastroenterology in her study. Her Midostaurin study in the realm of Myeloid leukemia connects with subjects such as In patient.
Her research investigates the connection between Oncology and topics such as Disease that intersect with issues in DNA sequencing. Her Cancer research research is multidisciplinary, relying on both Haematopoiesis, Gene expression, Gene, Gene knockdown and Progenitor cell. Her Leukemia study deals with Randomized controlled trial intersecting with Retinoic acid.
Her primary areas of study are Myeloid leukemia, Internal medicine, Cancer research, Oncology and Leukemia. Her Myeloid leukemia study incorporates themes from Germline mutation, Tp53 mutation, Variant allele, NPM1 and T. Konstanze Döhner focuses mostly in the field of Internal medicine, narrowing it down to matters related to Gastroenterology and, in some cases, Dasatinib, Confidence interval, Toxicity and Core binding factor acute myeloid leukemia.
Her Cancer research research includes themes of Haematopoiesis, Progenitor cell and Chromatin, Gene, Gene isoform. Her studies in Oncology integrate themes in fields like White blood cell and Gemtuzumab ozogamicin. Her Leukemia research is multidisciplinary, incorporating perspectives in Myeloid and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner;Stephan Stilgenbauer;Axel Benner;Elke Leupolt.
The New England Journal of Medicine (2000)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert.
Cancer Cell (2005)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil;Moritz Gerstung;Lars Bullinger;Verena I Gaidzik.
The New England Journal of Medicine (2016)
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk;Konstanze Döhner;Jürgen Krauter;Stefan Fröhling.
The New England Journal of Medicine (2008)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann.
The New England Journal of Medicine (2017)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F. Lo-Coco;G. Avvisati;M. Vignetti;C. Thiede.
The New England Journal of Medicine (2013)
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
Lars Bullinger;Konstanze Döhner;Eric Bair;Stefan Fröhling.
The New England Journal of Medicine (2004)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
Konstanze Döhner;Richard F Schlenk;Marianne Habdank;Claudia Scholl.
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka;Richard F. Schlenk;Verena I. Gaidzik;Marianne Habdank.
Journal of Clinical Oncology (2010)
Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations
Tobias Rausch;David T.W. Jones;Marc Zapatka;Adrian M. Stütz.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: